Puromycin is a naturally occurring aminonucleoside antibiotic that inhibits protein synthesis by ribosome-catalyzed incorporation into the C-terminus of elongating nascent chains, blocking further extension and resulting in premature termination of translation. It is most commonly known as a selection marker for cell lines genetically engineered to express a resistance transgene, but its additional uses as a probe for protein synthesis have proven invaluable across a wide variety of model systems, ranging from purified ribosomes and cell-free translation to intact cultured cells and whole animals. Puromycin is comprised of a nucleoside covalently bound to an amino acid, mimicking the 3' end of aminoacylated tRNAs that participate in delivery of amino acids to elongating ribosomes. Both moieties can tolerate some chemical substitutions and modifications without significant loss of activity, generating a diverse toolbox of puromycin-based reagents with added functionality, such as biotin for affinity purification or fluorophores for fluorescent microscopy detection. These reagents, as well as anti-puromycin antibodies, have played a pivotal role in advancing our understanding of the regulation and dysregulation of protein synthesis in normal and pathological processes, including immune response and neurological function. This manuscript reviews the current state of puromycin-based research, including structure and mechanism of action, relevant derivatives, use in advanced methodologies and some of the major insights generated using such techniques both in the lab and the clinic.

© 2020 The Author. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Puromycin is produced by *Streptomyces alboniger*, a gram-positive actinomycete, through a series of enzymatic reactions starting from adenosine triphosphate (ATP) [1]. Structurally, puromycin resembles the 3′ end of aminoacylated tRNA (aa-tRNA), with a modified adenosine base covalently linked to a tyrosine amino acid [2]. The major difference lies in the nature of the bond

![Diagram](image-url)

**Fig. 1. Puromycin structure and mechanism of action.** (A) Chemical structures of the 3′ end of an aminoacylated tyrosyl-tRNA (left) and puromycin (right). The different bonds between the nucleoside and amino acid moieties are shown in pink. (B) Basic mechanism of puromycin action. During translation elongation, aa-tRNA enters the A-site and accepts the nascent polypeptide chain from the peptidyl-tRNA in the P-site. Following translocation, the A-site becomes available to accommodate the next aa-tRNA (top). Like aa-tRNA, puromycin can enter the A-site and accept the nascent chain. This results in translation termination, ribosome disassembly and release of the nascent chain bearing a 3′ puromycin (bottom). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
between the amino acid and the ribose—a labile ester in aa-tRNA versus a stable peptide bond in puromycin (Fig. 1A). Similar to aa-tRNA, puromycin can enter the ribosomal A-site, where its free amino group accepts a nascent polypeptide chain from the P-site peptidyl-tRNA, in a reaction catalyzed by the ribosome peptidyl-transferase center (PTC). However, because the peptide bond between the two moieties of puromycin cannot be further cleaved by an incoming aa-tRNA, such incorporation into the C-terminus of elongating nascent chains prevents additional extension and results in irreversible premature termination of translation. This reaction, termed puromycylation, is energy independent and leads to disassembly of 80S ribosomes and release of peptidyl-puromycin products (Fig. 1B) [3,4]. C-terminal incorporation is considered to be the major inhibitory mechanism of puromycin, although some evidence points towards additional effects on ribosome recycling or other ribosome-associated functions [5,6]. After translation termination, truncated puromycylated polypeptides are rapidly targeted for degradation [7,8], suggesting that these newly synthesized products are recognized as aberrant by quality control mechanisms and cleared to avoid proteotoxic stress.

Despite its structural homology to tyrosyl-tRNA, puromycin incorporation is not amino acid specific. It is thought to occur at similar rates across all nascent polypeptide chains regardless of their sequence, and is therefore unaffected by the endogenous pools of amino acids or their relative content in the proteins being synthesized [9]. While the tyrosine moiety can be substituted with tryptophan without appreciable loss of activity, other naturally occurring L-amino acids significantly reduce the inhibitory effects of puromycin and some, such as glycine or proline, prevent puromycylation altogether [10]. Consistent with absence of codon-anticodon interactions, such substitutions do not increase or decrease the rate of puromycylation at positions coding for the substituted amino acids. Nevertheless, other interventions can enhance or suppress puromycylation. Pretreatment with cycloheximide, an inhibitor of ribosome translocation, can limit puromycin incorporation by blocking peptidyl-tRNA release, possibly by stabilizing a ribosome translational intermediate that increases A-site availability [4,12]. However, these effects may vary between cell types and experimental conditions, as some reports suggest that emetine inhibits puromycylation [13] while cycloheximide promotes it [14]. Based on these observations, as well as reports showing preferential incorporation of puromycin at specific positions during in vitro translation of model proteins, it has been proposed that puromycylation may occur more efficiently under conditions associated with reduced A-site occupancy e.g. during ribosome pausing on rare codons [5,15].

### Table 1

| Compound                         | Description                                      | Uses                                                                 |
|----------------------------------|--------------------------------------------------|----------------------------------------------------------------------|
| Nucleoside substitutions         |                                                  |                                                                     |
| 5’ Fluorophore-dec-puromycin     | Cy3, Cy5, or fluorescein attached via deoxycytidine linker | Imaging protein synthesis in cells [23]; In vitro C-terminal labeling of full-length proteins [24] |
| 5’ Biotin-dec-puromycin          | Biotin attached via deoxycytidine linker          | Labeling newly synthesized proteins under cell free conditions for subsequent affinity purification and proteomic analysis [25,26] |
| 5’ alkynel/azide puromycin (5Y/5Z/5N/5T) | Alkynel/azide substitution of the 5’ hydroxyl group | Labeling newly synthesized proteins in cultured cells for visualization or affinity purification using click chemistry cyclodaddition of fluorophore/biotin [19] |
| Amino acid substitutions         |                                                  |                                                                     |
| O-propargyl-puromycin (OPP)      | Alkynel substitution of the O-methyl-phenyl ring  | Labeling newly synthesized proteins in cultured cells, tissues and whole animals for visualization or affinity purification using click chemistry cyclodaddition of fluorophore/biotin [27] |
| Photocleavable N-blocked OPP     | Photocleavable group attached to the free amino terminus | Labeling newly synthesized proteins in cultured cells with improved spatialtemporal resolution using laser excitation [17,18] |
| Enzyme labile N-blocked OPP      | Enzyme labile phenylacetyl group attached to the free amino terminus | Selective labeling of newly synthesized proteins in cultured cells engineered to express an E. coli enzyme [28] |
| N-blocked biotin puromycin (3P)  | Biotin attached to the free amino terminus via double Jeffamine linker | Affinity purification of ribosomes under cell free conditions (without puromycylation) [16] |

### 2. Puromycin-based reagents

Since the discovery of its chemical structure, puromycin has been modified using both nucleotide and amino acid chemistries, generating a wide range of radiolabeled, fluorescent, biotinylated and photoactivatable derivatives (summarized in Table 1). It quickly became clear that the amino acid moiety of puromycin could only tolerate minor substitutions without a significant loss of activity, and that the free amino group is essential for inhibition of protein synthesis [5,10]. However, modifications of the nucleoside were generally better tolerated. Conjugation of puromycin to the 3’ end of a cytidine nucleotide or dinucleotide through phosphodiester bonds, mimicking the conserved CCA tail found in tRNAs, resulted in compounds that retained a relatively strong inhibitory effect; longer oligonucleotide extensions, however, were associated with drastic loss of function [5]. A cytidine nucleotide was used as a linker to introduce other functional groups without substantially affecting the inhibitory potential of the product, generating biotin- or fluorophore-dec-puromycin conjugates that mediate efficient puromycylation in cell-free systems. Blocking the free amino group yields products that cannot inhibit protein synthesis but may be otherwise useful, as some still bind ribosomes with high affinity [16]. When blocked with photolabile protecting groups e.g. O-Nitroveratryloxy carbonyl (NVOC) or 7-Diethylamino-4-methylcoumarin (DEACM), the resulting compounds show minimal toxicity but expose their amino group and undergo puromycylation upon UV irradiation, serving as a photoactivatable puromycin [17,18]. Some small modifications of the O-methyl-phenyl ring can also be tolerated without significant loss of function, such as the introduction of an alkynel group in O-propargyl-puromycin (OPP), which allows subsequent manipulation of puromycylated proteins by copper-catalyzed alkynel-azide cyclodaddition of a “clickable” biotin or fluorophore [8]. More recently, clickable puromycin reagents were expanded to include various alkynel or azide substitutions of either the nucleoside or amino acid moiety [19]. Another related reagent in the puromycin toolbox is the anti-puromycin antibody, first developed as a rabbit polyclonal [20,21] and later replaced by a commercial mouse monoclonal (clone 12D10) [22]. Both antibodies were raised by covalently attaching puromycin to a carrier protein via peptide bond formation, resembling the product formed by ribosome-catalyzed incorporation.
3. Uses of puromycin and puromycin-based techniques

Puromycin inhibits protein synthesis in organisms across all kingdoms of life, including its producer bacteria. However, S. albo\niger also expresses an enzyme called puromycin N-acyetyltransferase (pac), which acetylates and blocks the reactive amino group in puromycin, thus preventing peptide bond formation and conferring resistance. Puromycin resistance also occurs naturally in other organisms e.g. Saccharomyces cerevisiae due to limited permeability or presence of drug resistance factors, which can be reversed by genetic manipulations [29]. In the 1980s, pac was first cloned and expressed in mammalian cells to render them resistant to puromycin [30]. It has since become a popular method for selection of stably transformed or genetically engineered cells, seemingly without major perturbations to normal cellular function, although the expression of pac and the presence of N-acytelylated puromycin may have some effects on the cellular transcr\nptome [31,32]. Due to its non-selectivity and high systemic toxicity, puromycin never became a clinically relevant antibiotic, but has nevertheless been extensively used to study mechanisms of protein synthesis, particularly peptide bond formation by the PTC and ribosome translocation (reviewed in [33]). The next few sections describe the uses of puromycin beyond selection e.g. to measure protein synthesis rates, monitor subcellular localization of translating ribosomes, isolate nascent polypeptide chains and generate mRNA-protein fusions. A comparison of puromycin-based and alternative methods for probing translation is provided in Table 2.

3.1. Measurement of global protein synthesis

Regulation of protein synthesis is intimately linked to development and homeostasis at both the cellular and organismal level, and dysregulation has been implicated in many pathological states [34], underlining the importance of monitoring translation. Soon after the initial characterization of puromycin as an inhibitor of protein synthesis, levels of puromycylated peptides were found to be proportional to the overall rate of translation, rendering the puromycylation reaction a valuable tool for measuring changes in translation. The first probe, tritiated \[^{3}H\]puromycin, was used both in vitro [35] and in vivo [36] to demonstrate that translation is inhibited in response to starvation and stimulated in response to insulin administration. However, radioactive puromycin was discarded in favor of metabolic labeling using radioactive amino acids e.g. \[^{3}H\]leucine and \[^{35}S\]methionine/cysteine. These became the gold standard for translation rate measurements as they more directly reflect the normal physiological process, and because multiple radioactive labels can be incorporated into a single nascent chain without causing termination, allowing sequential rounds of translation and increasing final signal intensity. Nevertheless, radioactive and other amino acid analogs are significantly limited by competition with the endogenous pools, often restricting their use to conditions that allow predepletion and rendering them inapplicable for in vivo labeling.

More recently, antibody-coupled detection of puromycylated peptides was introduced as a nonradioactive alternative to traditional metabolic labeling. In its simplest application, low concentrations of puromycin are added to cultured cells or administered to animals, and puromycylated peptides are detected by standard immunoblotting using anti-puromycin antibodies, generating a complex laddering pattern that reflects the broad repertoire of newly synthesized proteins [22]. Other than immunoblotting, detection can take place by fluorescence activated cell sorting (FACS) using fluorophore-conjugated anti-puromycin antibodies. After addition of puromycin, puromycylated membrane proteins traffic from the ER to the plasma membrane, where they can be detected without disrupting the cells. In SUface SEnsing of Trans\lation (SU\nSET) (Fig. 2A), a 10-min pulse of puromycin followed by a 50-min chase resulted in detectable cell surface puromycylation in mouse embryonic fibroblasts (MEF). This was blocked by pre\treatment with either cycloheximide or Brefeldin A, which inhibits egress of membrane proteins from the ER. The signal generated was proportional to immunoblot detection and comparable to metabolic labeling using radioactive amino acids, supporting the use of SU\nSET as a proxy for measuring global translation rates [22]. A unique advantage of this approach is that translation can be measured at a single-cell resolution in parallel with other parameters e.g. mTOR activity, phosphorylation of translation factors and cell cycle phase. This allowed for the detection of cell-to-cell variability in steady-state inhibitory phosphorylation of elongation factor 2 (eEF2) and revealed an unexpectedly weak correlation between baseline eEF2 phosphorylation and global translation rates [37]. However, SU\nSET may not be readily applicable to all cell types, as puromycylated peptides were found to be absent from the surface of mouse bone marrow cells [27], suggesting that differences in plasma membrane composition or trafficking of membrane proteins may confound comparisons of SU\nSET between different cells or organisms.

The method described above has several variations. In one, OPP and fluorophores can replace puromycin and anti-puromycin antibodies. For example, OPP-labeled proteins were detected in mice as early as 1 h post-injection by fixing and permeabilizing extracted cells and coupling OPP to fluorescent azide. Incorporation of OPP can be similarly detected by either immunoblot or FACS, and

---

### Table 2

**Comparison of methods for probing translation.**

| Translation rate measurement | Puromycin reagents | Non-puromycin alternatives | Method of detection | Comments |
|-----------------------------|--------------------|---------------------------|---------------------|----------|
| Radioactive reagents        | Radioactive amino acids (AAs) [35] | Clickable AAs [56] | Scintillation or autoradiography Immunoblot or FACS | AA analogs do not terminate translation, but puromycin can be used without predepletion of endogenous AAs |
| Visualizaton of newly synthesized proteins | Puromycin/OPP (SUnSET) [8,22] | | | |
| Translatome analysis | Puromycin/OPP (RPM, Puro-PLA) [8,51,52] | Clickable AAs (FUNCAT, FUNCAT-PLA) [42,57] | Immunofluorescence | AA analogs do not terminate translation, but only puromycin can be used to label sites of active translation when combined with inhibitors of elongation |

| Translation | Puromycin reagents | N-blocked biotinylated puromycin (RibosomeLace) [16] | Deep sequencing of nuclease-resistant ribosome-protected mRNA (ribo-seq) [58] | Next generation sequencing | RiboLace can be used to affinity purify translating ribosomes prior to ribo-seq analysis |
|-------------|--------------------|---------------------------------------------------|-------------------------------------------------|--------------------------|-----------------------------------------------------------|
| Puromycin/OPP (PUNCH-P/OPP-ID) [44,47] | Biotinylated puromycin/OPP | AA isotopes (SILAC) [59] Clickable AAs (BONCAT/QuaNCAT) | Mass spectrometry | AA analogs do not terminate translation, but puromycinylation is rapid, AA nonspecific and can occur on isolated ribosomes |

---

**Table 2**

Comparison of methods for probing translation.
may have some advantages over antibody detection in terms of signal strength \[27,38\]. In another variation, ribosome runoff is induced by pretreatment with inhibitors of translation initiation. In SUnSET-based Ribosome Speed of Elongation (SunRISE) \[37\], a short pulse of harringtonine, which blocks initiation, leads to partial termination of elongating ribosomes prior to addition of puromycin. The difference in the levels of puromycylated peptides between pretreated and control cells is directly proportional to the extent of ribosome runoff and therefore provides an estimate of elongation rates. In MEFs, addition of puromycin at regular intervals from 30 s to 10 min after harringtonine was associated with a gradual reduction in the overall levels of puromycylated peptides detected by either immunoblotting or FACS. Signal decay was proportional to peptide length, with rapid loss of smaller puromycylated peptides, consistent with quicker termination of ribosomes translating shorter transcripts \[37\].

3.2. Subcellular localization of translating ribosomes and newly synthesized proteins

Puromycin can also be used to visualize translating ribosomes or translation products by immunofluorescence microscopy. In an early report, mouse dendritic cells (DC) were treated with puromycin for 30 min and then fixed, permeabilized and stained with antibodies against protein of interest. Puromycin incorporation into nascent chains can be detected by cell-free translation, incorporation of puromycin by ribosomes that reach the stop codon links the nascent polypeptide to its cognate transcript. These mRNA-protein fusion products are then selected by binding to bait proteins or nucleic acids and amplified by error-prone PCR for additional rounds of selection prior to detection by next generation sequencing.
an anti-puromycin antibody. This revealed that, during DC maturation in response to inflammatory challenge, newly synthesized proteins are sequestered in aggregates called DC aggresome-like induced structures (DALIS) where they are protected from degradation [39]. Ribopuromycylation (RPM) microscopy [14] went one step further, adding an emetine pretreatment step to retain puromycylated peptides on ribosomes thus allowing in situ visualization of active translation sites (Fig. 2B). Puromycylation in the presence of emetine had the same effect on SUNSET as brefeldin A, consistent with emetine preventing the release of nascent chains from ribosomes and subsequent trafficking to the cell surface. Colocalization of puromycylated peptides and ribosomal proteins was found to be high but incomplete, likely due to the presence of idle ribosomes. When applied to cells infected with vaccinia virus, which renders most ribosomes idle except for a subset that is recruited to sites of viral biosynthesis, RPM revealed that ribosomal proteins are scattered throughout the cytoplasm but only colocalize with puromycylated peptides in these so-called viral factories [14]. Nevertheless, the subcellular localization of newly synthesized proteins detected by puromycin microscopy may be different than that obtained by amino acid analogs [8], advising some caution in interpreting the results of such experiments. Similar to other techniques, puromycin derivatives can be substituted for antibodies in RPM. While bulky biotin or fluorophore derivatives cannot promote rapid and efficient puromycylation in cultured cells or whole animals due to either low permeability or reduced affinity to the ribosome A-site [23], uptake and incorporation of the smaller OPP, followed by fixation and fluorophore cyclodaddition, was successfully employed to visualize protein synthesis in situ [8,40,41].

Puromycin-based microscopy can also be coupled with proximity ligation (PLA) to detect the distribution and turnover of specific newly synthesized proteins, based on spatial proximity between an antibody against puromycin and another antibody against a specific protein of interest [42]. In puro-PLA, cultured cells are puromycylated, fixed and incubated with two primary antibodies raised in affinity purified antibodies bind to the same protein molecule. Ligation forms a closed oligonucleotide loop for rolling circle amplification, and the amplified product is detected by a complementary fluorescent probe (Fig. 2C). This technique has been used to visualize sites of translation of specific proteins in neuronal cells [42,43]. PLA can also be combined with clickable amino acids, but puro-PLA may have some advantages e.g. shorter incubation times and higher signal [37].

3.3. Isolation of nascent chains and untagged ribosomes

Cell-free puromycylation enables the labeling of nascent chains on ribosomes isolated from cells or tissues, thus avoiding potential stress-related effects triggered by the presence of truncated peptides. This principle guided the development of Pluromycin-associated Nascent CHain Proteomics (PUNCH-P) [44], in which translating ribosomes are first isolated by ultracentrifugation, and nascent chains are then labeled in vitro with biotin-DC-puromycin, captured on streptavidin beads and analyzed by mass-spectrometry (MS) (Fig. 2D). This technique capitalizes on the high affinity between biotin and streptavidin to generate a snapshot of the nascent proteome at the time of lysis. PUNCH-P detected over 5000 nascent chains in HeLa cells and about 2000 in mouse brains, and was used to identify rapid cell cycle variations in translation and degradation rates, revealing a regulated lag between transcription, translation and protein accumulation [25,45]. PUNCH-P was also combined with quantitative isotope labeling proteomics to show that a large proportion of nascent chains are cotranslationally degraded by the proteasome, including proteins involved in ribosome biogenesis and translation, nuclear transport and amino acid metabolism [46]. Co-translational degradation rates were found to correlate with translation efficiency and protein length, but not half-life of the mature protein counterparts [46]. As an alternative to biotin-DC-puromycin, nascent chains can be isolated from OPP-treated cells or animals by coupling to biotin prior to streptavidin capture and MS (OPP-ID). This minimizes potential biases introduced by the ribosome isolation procedure but is also susceptible to stress-related effects. Furthermore, this and other techniques based on incorporation of amino acid analogs have so far exhibited lower sensitivity, with about 300 newly synthesized proteins measured after a 2 h pulse of OPP in MEFs [47] and 400 proteins detected in brain tissue after a 2 day feeding of mice with clickable amino acids [48]. Finally, puromycin can be used to stably capture ribosomes without tagging ribosomal proteins; when modified with a biotin linker on its amino group, puromycin binds the ribosome but is unable to form a peptide bond. As such, it is a poor inhibitor of translation but a high affinity ribosome ligand. By immobilizing this biotinylated derivative of puromycin on streptavidin beads, translating ribosomes can be affinity purified from cell lysates together with the mRNA templates they harbor, for further processing or analysis such as by ribosome profiling (ribo-seq) [16].

3.4. Protein labeling and formation of mRNA-peptide fusions

At low non-inhibitory concentrations, about two orders of magnitude less than those commonly used for selection, puromycin cannot effectively compete with aa-tRNA and therefore only becomes incorporated when ribosomes reach a stop codon, generating C-terminal labeling of full-length proteins. This was revealed through cell-free translation of a transcript bearing multiple methionines immediately upstream to a stop codon. Escherichia coli translation reactions were supplemented with radioactive methionine, and products were digested with a carboxypeptidase that cleaves after terminal amino acids but not puromycin. Adding low concentrations of puromycin to the reaction mix did not affect the overall amount of protein product, but protected it from cleavage of the terminal methionines [49]. Furthermore, depletion of translation termination factors and addition of ribosome recycling factors increased labeling efficiency [50], further supporting the proposed mechanism of action. This approach was used to generate proteins labeled on their C-terminus with fluorescent or biotinylated puromycin, later to be used as probes for protein–protein and protein–nucleic acid interaction studies [51,52].

Another technique based on incorporation of puromycin into full-length proteins is called mRNA display or in vitro virus (IVV) [53]. This is an in vitro display technique for protein selection and evolution that establishes a physical link between genotype and phenotype. mRNA is transcribed from a cDNA library, then conjugated to a non-coding oligonucleotide spacer with a 3’ puromycin through enzymatic ligation or chemical crosslinking. The resulting transcripts are translated in a cell-free system e.g. rabbit reticulocyte lysate, where the incorporation of puromycin by ribosomes that pause on the 3’ end of coding mRNA fuses nascent polypeptides to their cognate transcripts (Fig. 2E). For directed evolution experiments, the resulting products are affinity purified by binding to immobilized bait proteins or nucleic acids, reverse transcribed and then amplified using error prone PCR or saturation mutagenesis to introduce additional variation, thereby increasing library diversity for the next round of selection. A similar principle can also be used to fabricate protein chips by in situ translation of mRNA-puromycin fusions immobilized to streptavidin-coated slides [34]. Puromycin-based mRNA display has some advantages over the more commonly used phage or yeast display techniques.
Libraries can be larger, with up to trillions of mRNAs, and avidity effects are avoided because each ribosome can only display a single protein copy. The cell-free conditions also allow for incorporation of unnatural amino acids to improve affinity, permeability or stability, and the mutational landscape can be better explored. However, mRNA display is limited by the instability of RNA under various selection conditions, as well as the low efficiency of fusion formation, which can be improved by introduction of rare codons in the 3’ end of coding regions [15].

4. Biological insights generated using puromycin-based techniques

4.1. Immune response and nuclear translation

During an immune response, environmental changes can cause stress that in most cell types results in near-complete shutoff of all major biosynthetic functions. However, immune cells have different resistance mechanisms to maintain their functions under stress. Activation of such cells, as measured by in vivo puromycin labeling, is associated with several fold induction of translation rates [61]. To alert the immune system to potential pathogens, proteins are rapidly degraded and presented by class I major histocompatibility complex (MHC). Puromycin-based microscopy revealed that a major source of such peptides is defective ribosomal products (DRiPs)—nascent polypeptides that fail to fold or complete their synthesis and are targeted for proteasomal degradation. During maturation, antigen-presenting DCs rapidly sort DRiPs into cytosolic granules for storage, to delay peptide presentation until migration to lymph nodes or the spleen [39]. These are then targeted for degradation with the help of molecular chaperones [62]. Using OPP, DRiPs were also found to diffuse into the nucleus where they form nuclear aggregates that, if not cleared by proteasomes, lead to depletion of ubiquitin and defects in DNA repair [63,64].

Similar immunofluorescent puromycylation experiments also provided compelling evidence in support of nuclear translation. It was long known that all components of the translation apparatus can be found in the nucleus, including ribosomal proteins, translation factors and tRNAs, but whether or not these individual components actively engage in protein synthesis is still controversial. Puromycylation was detected in the nucleoplasm and nucleolus of multiple cell types, including Hela cells, primary monocytes [14] and drosophila S2 cells, where the signal accumulated around chromosomes at transcriptionally active sites [13]. Puromycin signal in the nucleus was eliminated by harringtonine and enhanced by emetine, suggesting that it depends on ribosome catalysis and is not secondary to import of proteins synthesized in the cytoplasm. Nuclear staining was also eliminated upon infection with vaccinia virus, which confines translating ribosomes to perinuclear viral factories [14]. Nuclear translation was proposed to serve as a quality control mechanism, similar to the cytoplasmic pioneer round of translation that surveys and aborts transcripts with premature stop codons [65]. Indeed, nuclear translation was shown to be a source of antigenic peptides presented by MHC I [66]. Antigenic peptides were found to be produced even when their coding sequences were introduced into introns that are spliced out prior to nuclear export, suggesting that translation of prespliced mRNAs occurs in the nucleus and contributes to immunological surveillance [67].

4.2. Neurological function and axonal translation

Early studies into the acquisition of long-term memory showed that intracranial injections of puromycin in goldfish [68] and mice [69] were associated with amnestic effects following shock aversion training, establishing a role for de novo protein synthesis in consolidation of learning-induced synaptic changes. More recently, in vivo puromycin labeling revealed that global translation rates are reduced in Down Syndrome due to constitutive activation of the integrated stress response [70], but elevated in a mouse model of autism due to hyperactivation of translation initiation factor 4E (eIF4E) [71], expanding the link between translation dysregulation and neurological dysfunction. eIF4E hyperactivation was also reported in Huntington’s disease, leading to increased translation of oxidative phosphorylation proteins and decreased translation of neuron-specific factors, as measured by PUNCH-P [26]. Furthermore, in vivo and in situ puromycylation showed that a specific splice isoform of initiation factor 4G (eIF4G) is associated with ribosome stalling due to recruitment of factors that promote RNA granule nucleation, and its depletion results in increased protein synthesis and cognitive impairment in mice [72]. Similar methods were used to show that expression of pathological Tau, implicated in Alzheimer’s disease, reduces translation of ribosomal proteins and translation factors in patient cells and mouse brains, leading to shortage of ribosomes [73,74], whereas deletion of Tau increases protein synthesis and enhances long-term memory in drosophila neurons [75].

At the subcellular level, localized protein synthesis is a common feature of pre- and post-synaptic neuronal compartments [76]. Puromycin microscopy detected a large proportion of the neuronal transcriptome in granules containing stalled ribosomes, which travel from the soma to the synapse, allowing regulated reactivation of translationally-paused mRNAs. This ensures rapid synaptic synthesis in response to stimulus, even under conditions that inhibit translation initiation [77], and is critical for both axonal development and homeostasis [78]. Proteomic analysis of OPP-treated mouse neurons revealed that, in response to nerve injury, mammalian target of rapamycin (mTOR) activates local translation of its own mRNA as well as that of other genes involved in injury signaling [79]. Even without pretreatment to block elongation, puromycylated peptides remain associated with ribosomes in axons but become released from ribosomes in the cell soma, confirming the axonal-specific presence of stalled ribosomes [80]. These stalled ribosomes can associate with late endosomes, which serve as a moving platform for localized translation, particularly of pro-survival mitochondrial proteins [81]. Localized synaptic translation was further detected by electron microscopy: cultured hippocampal neurons were pulsed with puromycin, fixed and analyzed using an immunogold labeled anti-puromycin antibody, showing discrete puromycin-positive puncta in both dendrites and synapses [43]. Strikingly, these were recently found to consist mostly of elongating 80S monosomes rather than polysomes, possibly allowing more precise control of protein copies in the synapse [82].

4.3. Protein evolution and interactome studies

mRNA display has been used to screen for antibodies and protein ligands, and some of the resulting products have been evaluated not only in the lab but also in clinical settings [83]. One unique advantage of this approach is the ability to screen for cyclic peptides, which offer benefits such as locking the peptide in its biologically active conformation, restricting proteolytic cleavage and improving membrane permeability. Natural cyclic peptides are most commonly synthesized by enzymatic complexes called nonribosomal peptide synthetases, but mRNA display can incorporate unnatural amino acids that enable cyclization, providing a platform for their ribosomal synthesis [84,85]. This was used to develop a high-affinity protease-resistant cyclic peptide inhibitor against a disease-related G protein. A randomized library was first
screened for high affinity binders, and these were then evolved for resistance to proteolytic cleavage by preincubation with an immobilized protease [86]. mRNA display was also used to screen an antibody mimetic library for pathogen receptor binders that, when fused to an antigenic peptide, triggered presentation by DCs and stimulated an immune response [87]. The same library was combined with continuous flow magnetic separation for single-round selection of immunoglobulin binders, resulting in identification of candidates with comparable affinity to that of protein A and protein G, for potential research or industrial use [88]. In another application, a library constructed from mouse brain poly-A mRNA was selected using bait DNA, generating large scale interaction data for multimeric complexes of transcription factors or other DNA-binding proteins [89].

4.4. Clinical diagnosis and treatment

Measurement of protein synthesis rate in cancer patients can guide treatment decisions and is important for long term survival. Radiolabeled amino acids showed unsatisfactory results as tracers of protein synthesis, but puromycin labeled with radioisotopes e.g. Gallium-68 [90], Scandium-44 [91] or Fluorine-18 [92] holds promise as a radiopharmaceutical for positron emission tomography (PET). Tumor uptake of radiolabeled puromycin was not only significant and rapid, but also, and unlike amino acids, proportional to and dependent on protein synthesis. In the body, puromycin is metabolized into a nephrotoxic metabolite called puromycin aminonucleoside; this metabolite is used to induce kidney damage in an animal model called puromycin aminonucleoside nephrosis (PAN), which mimics nephrotic syndrome in humans [93]. Puromycin also inhibits several aminopeptidases, including puromycin-sensitive aminopeptidase (PSA), which is involved in the proteolytic clearance of aggregation-prone substrates [94]. Substitutions of the methyl phenyl group in puromycin yield potent aminopeptidase inhibitors with minimal effects on protein synthesis, and these compound are being evaluated as candidates for the treatment of hematologic malignancies associated with elevated aminopeptidase activity [95]. Puromycin may also hypersensitize cells to chemotherapy by enhancing p53-dependent apoptosis [96]. Finally, blocked puromycin derivatives are evaluated as prodrugs for selective cancer therapy. In one strategy, blocking the free amino group by an acetylated lysine generates a masked cytotoxic agent, which is specifically activated by histone deacetylase and cathepsin L, two enzymes known to be overexpressed in some cancers [97,98].

5. Summary and outlook

Since its discovery over half a century ago, puromycin has helped shape our understanding of ribosome function and protein synthesis kinetics. It laid the groundwork for establishing a link between translation regulation and fundamental biological processes across a diverse range of normal development and disease models, including cancer, viral infection and neurodegeneration. The toolbox of puromycin-based reagents has grown considerably over the past decade, with antibodies and derivatives opening up new avenues of research and biotechnological applications. While amino acid analogs may offer a more direct approach to measuring and visualizing translation, puromycin-based techniques have some unique advantages: they are robust, highly sensitive, amino acid nonspecific and applicable for cell-free, intact cells and whole animal systems without requiring pretreatment or predepletion of endogenous amino acids.

Nevertheless, additional work is required to better characterize potential biases associated with puromycylation. Truncated puromycylated peptides are recognized by quality control mechanisms as aberrant [7,8], and this could introduce confounding variables e.g. increased aggregation and degradation or altered gene expression. Therefore, puromycin-based techniques are generally considered inapplicable for studying protein synthesis over extended periods of time. At high concentrations, puromycin was suggested to inhibit protein synthesis via peptide bond-independent mechanisms [5], which could further complicate data interpretation. Differences in puromycin uptake or rate of puromycylation and trafficking of membrane proteins may confound comparisons of cell surface puromycylation between cell types [27]. Furthermore, structural variations between endogenous amino acids, amino acid analogs and puromycin-based reagents may affect A-site affinity and therefore incorporation specificity. Indeed, discrepancies in labeling pattern, including molecular weight distribution and subcellular localization, have been observed between different puromycin and amino acid analogs [8,19]. One study showed that such discrepancies are exacerbated under specific cellular conditions e.g. glucose starvation [99]. While some of these differences may be attributed to the amino acid nonspecific nature of puromycylation, they could also reflect preferential incorporation of puromycin at sites of ribosome pausing [5,15] due to e.g. rare codons, RNA secondary structures, or limited availability of tRNAs and translation factors.

Each of the methods discussed above has its strengths and weaknesses. Therefore, combining complementary puromycin-based and alternative techniques for monitoring translation could offer a broader, more robust perspective. Regardless of the above caveats, puromycin still holds great promise for improving our understanding of ribosome function and global as well as transcript-specific translation regulation in health and disease.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Funding to open access publication charge was provided by NIH grant GM056433.

References

[1] Tercero JA, Espinosa JC, Lacalle RA, Jiménez A. The biosynthetic pathway of the aminonucleoside antibiotic puromycin, as deduced from the molecular analysis of the pur cluster of Streptomyces alboniger. J Biol Chem 1996;271(3):1579–90. https://doi.org/10.1074/jbc.271.3.1579.
[2] Yarmolinsky MB, Haba GL. Inhibition by puromycin of amino acid incorporation into protein. Proc Natl Acad Sci USA 1959;45(12):1721–9. https://doi.org/10.1073/pnas.45.12.1721.
[3] Semenkov YU, Shapkina T, Makhno V, Kirillov S. Puromycin reaction for the A site-bound peptide–tRNA. FEBS Lett 1992;296(2):207–10. https://doi.org/10.1016/0014-5793(92)80380-y.
[4] Baliga BS, Cohen SA, Munro HN. Effect of cycloheximide on the reaction of puromycin with polysome-bound peptide–tRNA. FEBS Lett 1970;4(5):249–52. https://doi.org/10.1016/0014-5793(70)80278-2.
[5] Starck SR, Roberts RW. Puromycin oligonucleotides reveal steric restrictions for ribosome entry and multiple modes of translation inhibition. RNA 2002;8(7):890–903. https://doi.org/10.1016/s1355-8382(02)02005-9.
[6] Kandala DT, Del Piano A, Minati L, Clamer M. Targeting translation activity at the ribosome interface with UV-active small molecules. ACS Omega 2019;4(6):10336–45. https://doi.org/10.1021/acsomega.9b03606.
[7] Goldberg AL. Degradation of abnormal proteins in Escherichia coli (protein breakdown–protein structure–translation–amino acid analogs–puromycin). Proc Natl Acad Sci USA 1972;69(2):422–6. https://doi.org/10.1073/pnas.69.2.422.
[8] Liu J, Xu Y, Stoleru D, Salic A. Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin. Proc Natl Acad Sci USA 2012;109(2):413–8. https://doi.org/10.1073/pnas.1111561108.
1082

[33x741]1082

[33x315]1082

[33x243]1082

[33x370]1082

[33x498]1082

[33x570]1082

[33x68]1082

[33x211]1082

[33x697]1082

[33x171]1082

[33x99]1082

[33x147]1082

[33x458]1082

[33x83]1082

[33x139]1082

[33x227]1082

[33x410]1082

[33x179]1082

[33x434]1082

[33x251]1082

[33x482]1082

[33x705]1082

[33x293]1082

[33x386]1082

[33x506]1082

[33x514]1082

[33x522]1082

[33x524]1082

[33x546]1082

[33x530]1082

[33x554]1082

[33x562]1082

[33x578]1082

[33x586]1082

[33x594]1082

[33x602]1082

[33x625]1082

[33x641]1082

[33x649]1082

[33x657]1082

[33x665]1082

[33x681]1082

[33x699]1082

[33x707]1082

[33x713]1082

[33x719]1082

[33x721]1082

[33x723]1082

[33x725]1082

[33x727]1082

[33x729]1082

[33x731]1082

[33x733]1082

[33x735]1082

[33x737]1082

[33x739]1082

[33x741]1082

[33x743]1082

[33x745]1082

[33x747]1082

[33x749]1082

[33x751]1082

[33x753]1082

[33x755]1082

[33x757]1082

[33x759]1082

[33x761]1082

[33x763]1082

[33x765]1082

[33x767]1082

[33x769]1082

[33x771]1082

[33x773]1082

[33x775]1082

[33x777]1082

[33x779]1082

[33x781]1082

[33x783]1082

[33x785]1082

[33x787]1082

[33x789]1082

[33x791]1082

[33x793]1082

[33x795]1082

[33x797]1082

[33x799]1082

[33x801]1082

[33x803]1082

[33x805]1082

[33x807]1082

[33x809]1082

[33x811]1082

[33x813]1082

[33x815]1082

[33x817]1082

[33x819]1082

[33x821]1082

[33x823]1082

[33x825]1082

[33x827]1082

[33x829]1082

[33x831]1082

[33x833]1082

[33x835]1082

[33x837]1082

[33x839]1082

[33x841]1082

[33x843]1082

[33x845]1082

[33x847]1082

[33x849]1082

[33x851]1082

[33x853]1082

[33x855]1082

[33x857]1082

[33x859]1082

[33x861]1082

[33x863]1082

[33x865]1082

[33x867]1082

[33x869]1082

[33x871]1082

[33x873]1082

[33x875]1082

[33x877]1082

[33x879]1082

[33x881]1082

[33x883]1082

[33x885]1082

[33x887]1082

[33x889]1082

[33x891]1082

[33x893]1082

[33x895]1082

[33x897]1082

[33x899]1082

[33x901]1082

[33x903]1082

[33x905]1082

[33x907]1082

[33x909]1082

[33x911]1082

[33x913]1082

[33x915]1082

[33x917]1082

[33x919]1082

[33x921]1082

[33x923]1082

[33x925]1082

[33x927]1082

[33x929]1082

[33x931]1082

[33x933]1082

[33x935]1082

[33x937]1082

[33x939]1082

[33x941]1082

[33x943]1082

[33x945]1082

[33x947]1082

[33x949]1082

[33x951]1082

[33x953]1082

[33x955]1082

[33x957]1082

[33x959]1082

[33x961]1082

[33x963]1082

[33x965]1082

[33x967]1082

[33x969]1082

[33x971]1082

[33x973]1082

[33x975]1082

[33x977]1082

[33x979]1082

[33x981]1082

[33x983]1082

[33x985]1082

[33x987]1082

[33x989]1082

[33x991]1082

[33x993]1082

[33x995]1082

[33x997]1082

[33x999]1082

[33x1001]
Mediani L et al. Defective ribosomal products challenge nuclear function by impairing nuclear condensate dynamics and immobilizing ubiquitin. EMBO J 2019;38(15):1–19. https://doi.org/10.15252/embj.2018101341.

Uozumi N, Matsunowo H, Saitoh H. Detection of O-propargyl-puromycin with SUMO and ubiquitin by click chemistry at PML-nuclear bodies during abortive proteasome activities. Biochim Biophys Acta 2016;1847(2):247–51. https://doi.org/10.1016/j.bbagrm.2016.01.155.

Maquat LE, Tarn W-Y, Iken O. The pioneer round of translation: features and functions. Cell 2010;142(3):368–74. https://doi.org/10.1016/j.cell.2010.07.022.

Martins RP et al. Nuclear processing of nascent transcripts determines product-like macrocyclic peptides using in vitro display technologies. Curr Opin Chem Biol 2013;24:131–8. https://doi.org/10.1016/j.copcb.2013.11.011.

Zorzi A, Doyle K, Heinis C. Cyclic peptide therapeutics: past, present and future. Curr Opin Chem Biol 2017;38:24–9. https://doi.org/10.1016/j.copcb.2017.02.006.

Howell SM et al. Stemable natural peptides designed by mRNA display. Sci Rep 2014;4:6008. https://doi.org/10.1038/srep06008.

Koide S, Koide A, Lipovsek D. Target-binding proteins based on the 10th human fibronectin type III domain (Fn3). Methods Enzymol 2012;503:135–56. https://doi.org/10.1016/B978-0-12-696062-0.00006-9.

Olson CA et al. Single-round, multiplexed antibody mimetic design through mRNA display. Angew Chem Int Ed Engl 2012;51(50):12449–53. https://doi.org/10.1002/anie.201200595.

Batista AFR, Martínez JC, Hengst U. Intra-axonal synthesis of SNAP25 is a practical route to 3′-amino-3′-deoxyadenosine derivatives and puromycin analogues. J Org Chem 2003;68(5):2038–41. https://doi.org/10.1021/jo026272j.

Egner S et al. Imaging of protein synthesis: in vitro and in vivo evaluation of [44S]-DOTA-puromycin. Mol Imag Biol 2013;15(1):79–86. https://doi.org/10.1007/s11307-012-0961-3.

Bets HM et al. Synthesis, in vitro evaluation, and radiolabeling of fluorinated puromycin analogues: potential candidates for PET imaging of protein synthesis. J Med Chem 2016;59(20):9422–30. https://doi.org/10.1021/acs.jmedchem.6b00693.

Borowsky B, Kessler D, Recant L. Structural analogues of puromycin in production of experimental nephrosis in rats. Proc Soc Exp Biol Med 1958;97(4):857–60. https://doi.org/10.3181/00379727-97-23900.

Bhutani N, Venkatraman P, Goldberg AL. Puromycin-sensitive aminopeptidase is the major peptidase responsible for digesting polypeptide sequences released by proteasomes during protein degradation. EMBO J 2007;26(5):1385–96. https://doi.org/10.1038/sj.emboj.7601592.

Singh R, Williams J, Vince R. Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies. Eur J Med Chem 2017;139:325–36. https://doi.org/10.1016/j.ejmech.2017.07.048.

Jung JH et al. p53-dependent apoptotic effect of puromycin via binding of ribosomal protein L5 and L11 to MDM2 and its combination effect with RITA or doxorubicin. Cancers (Basel) 2019;11(4). https://doi.org/10.3390/cancers11040582.

Ueki N, Lee S, Sampson NS, Hayman MJ. Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease. Nat Commun 2013;4:2735. https://doi.org/10.1038/ncomms3735.

Marciano R, Leporever G, Rotblat B. Puromycin labeling does not allow protein synthesis to be measured in energy-starved cells. Cell Death Dis 2018;9(2):4–6. https://doi.org/10.1038/s41419-017-0056-x.